1. Amphetamine's CNS effects in ADHD involve both noradrenergic and dopaminergic pathways. Which of the following most accurately distinguishes the specific contributions of NE versus dopamine to the therapeutic effects of amphetamine in ADHD, and explains why both pathways must be engaged for full therapeutic efficacy?
A) Amphetamine's ADHD therapeutic effects are mediated entirely by dopamine release in the mesolimbic reward pathway -- the euphoric reward produced by dopamine in the nucleus accumbens motivates children with ADHD to pay attention; NE release contributes only the peripheral sympathomimetic side effects (tachycardia, appetite suppression) and plays no role in the cognitive therapeutic mechanism; this dopamine-only mechanism explains why methylphenidate (which has less NE versus dopamine effect ratio than amphetamine) is less effective than amphetamine for ADHD in most patients.
B) Amphetamine releases both NE and dopamine in the prefrontal cortex and subcortical circuits, and each neurotransmitter contributes distinct therapeutic effects: NE released in the prefrontal cortex (PFC) activates postsynaptic alpha-2A receptors on pyramidal neuron dendritic spines -- strengthening PFC network connectivity, improving working memory, and enhancing signal-to-noise ratio in attentional circuits; dopamine released in the PFC and striatum activates D1 receptors (Gs-cAMP, strengthening PFC network connections for goal-directed behavior) and D2 receptors (modulating striatal function and reward-related motivation); the combination of PFC noradrenergic (alpha-2A) and dopaminergic (D1) enhancement plus striatal dopaminergic modulation (D2) produces the full spectrum of ADHD therapeutic effects: improved working memory and attention (NE/PFC), reduced impulsivity (NE and DA/PFC), improved motivation and task engagement (DA/mesolimbic); purely selective NE agents (atomoxetine) improve attention and impulsivity but are less effective for the motivational and reward aspects of ADHD; purely dopaminergic agents alone address motivation but less effectively target the PFC attentional circuits.
C) Amphetamine's NE and dopamine effects in ADHD are therapeutically interchangeable -- NE and dopamine both activate the same Gs-cAMP signaling pathway at their respective receptors (alpha-2A-Gi for NE and D1-Gs for dopamine are both cAMP-modulating), and the downstream effects on PFC networks are identical; the clinical reason amphetamines work better than pure NE agents (atomoxetine) alone is simply that amphetamine produces more total monoamine release than atomoxetine's reuptake inhibition, providing greater receptor occupancy regardless of which monoamine is elevated.
D) Amphetamine's therapeutic ADHD mechanism involves only NE release -- the dopamine released by amphetamine is pharmacologically irrelevant to ADHD treatment because the prefrontal cortex expresses almost no dopamine receptors (dopamine receptors are concentrated in the striatum); the dopamine released by amphetamine goes to the mesolimbic system (causing euphoria and abuse potential) and the nigrostriatal system (causing potential motor tics); the therapeutic benefit of amphetamine is entirely noradrenergic, which explains why selective NE agents like atomoxetine are pharmacologically equivalent to amphetamine for ADHD.
ANSWER: B
Rationale:
Amphetamine's therapeutic effects in ADHD involve a carefully integrated noradrenergic-dopaminergic interplay across multiple brain circuits. Noradrenergic contribution in the PFC: NE released by amphetamine in the PFC (from locus coeruleus projections) acts at postsynaptic alpha-2A receptors on dendritic spines of pyramidal neurons in layer II/III of the dorsolateral PFC; alpha-2A Gi-mediated closure of HCN channels (which generate a hyperpolarizing Ih current that normally disconnects PFC synaptic inputs) strengthens synaptic connectivity and the persistent firing of PFC networks during working memory tasks; this is the same mechanism exploited by guanfacine and clonidine in ADHD; the NE/PFC effect improves working memory maintenance, attention regulation, and top-down inhibitory control of impulsivity; alpha-1 receptor activation at higher NE concentrations (stress states) produces the opposite effect (PFC shutdown -- shift to subcortical stimulus-driven behavior), explaining why stress worsens ADHD symptoms. Dopaminergic contributions: (1) PFC D1 receptors: Gs-cAMP activation at D1 receptors in the PFC strengthens the same PFC networks that NE modulates via alpha-2A, particularly for goal-directed, reward-relevant behaviors; D1 activation in PFC is crucial for motivated, purposeful attentional engagement; (2) Striatal D1 and D2 receptors: dopamine in the caudate and putamen modulates the cortico-striato-thalamo-cortical loops that regulate task-switching, habit learning, and reward-driven motivation; deficient striatal dopaminergic signaling in ADHD contributes to the motivational deficits and reward-seeking behavior that characterize the disorder; (3) Mesolimbic (nucleus accumbens) D1/D2: motivational engagement and task-reward salience. Integration: full ADHD therapeutic response requires both noradrenergic PFC optimization (attention, working memory, impulse control) AND dopaminergic PFC and striatal modulation (motivation, task engagement, habit regulation); this is why NE-selective agents (atomoxetine) are partially effective but often less so than amphetamines or stimulants that release both transmitters; and why dopamine-only approaches are also incomplete.
Option A: Option A is incorrect: amphetamine's ADHD therapeutic effects are not mediated entirely by dopamine release in the mesolimbic reward pathway; the mesolimbic dopamine system (VTA to nucleus accumbens) mediates reward, motivation, and euphoria — not the cognitive-enhancing effects relevant to ADHD treatment; the PFC NE effects of amphetamine (via alpha-2A receptor stimulation from released NE) are specifically important for ADHD improvement in attention, working memory, and impulse control.
Option C: Option C is incorrect: amphetamine's NE and dopamine effects in ADHD are not therapeutically interchangeable; NE in the PFC (via alpha-2A receptors) strengthens working memory networks and reduces impulsivity; dopamine in the PFC (via D1 receptors) optimizes signal-to-noise ratio in PFC circuits; these are distinct receptor-mediated mechanisms with different cognitive functions, not redundant pathways that can substitute for each other.
Option D: Option D is incorrect: amphetamine's dopamine effects are not irrelevant to ADHD treatment because the PFC lacks D1 receptors; the PFC does express D1 receptors in significant numbers, and D1 receptor activation (from increased PFC dopamine) is an important component of prefrontal cognitive enhancement; additionally, mesolimbic dopamine affects motivational aspects of ADHD (motivation to engage with tasks), which is also therapeutically important.
2. The interaction between MAO inhibitors and serotonergic drugs produces serotonin syndrome, while the interaction between MAO inhibitors and indirect sympathomimetics produces hypertensive crisis. Which of the following most accurately distinguishes the clinical presentations of these two MAOI-related emergencies and identifies the pharmacological basis for choosing different treatments for each?
A) Serotonin syndrome and hypertensive crisis from MAOI interactions are clinically identical because both involve excessive monoamine signaling; the only distinguishing feature is the precipitating drug class (serotonergic drugs cause serotonin syndrome, indirect sympathomimetics cause hypertensive crisis); both conditions are treated identically with phentolamine IV (which blocks both alpha-1 adrenergic receptors and serotonin 5-HT2A receptors with equal potency) because phentolamine was designed as a dual monoamine receptor antagonist.
B) Serotonin syndrome and MAOI-induced hypertensive crisis from indirect sympathomimetics are clinically and pharmacologically distinct emergencies: Hypertensive crisis (indirect sympathomimetic + MAOI): mechanism = massive NE release from sympathetic terminals (tyramine, pseudoephedrine, amphetamine) that cannot be inactivated by the inhibited intraneuronal MAO; predominant features = severe hypertension (systolic often greater than 200 mmHg), explosive headache, diaphoresis, pallor, palpitations, tachycardia; cardiovascular complications are the primary risk (intracranial hemorrhage, MI, aortic dissection); treatment = phentolamine IV (alpha-1/alpha-2 blocker directly reversing the NE-mediated vasoconstriction) or nitroprusside infusion; avoid beta-blockers. Serotonin syndrome (serotonergic drug + MAOI): mechanism = massive serotonin excess from combined SERT inhibition (SSRI, SNRI, meperidine, tramadol, dextromethorphan) plus MAO-A inhibition of serotonin degradation; predominant features = the clinical triad of (1) neuromuscular abnormalities: clonus (pathognomonic), hyperreflexia, myoclonus, ataxia; (2) autonomic instability: hyperthermia (can be extreme, greater than 41 degrees C), tachycardia, diaphoresis, variable BP; (3) altered mental status: agitation, confusion; clonus and hyperreflexia are the distinguishing features from hypertensive crisis (purely cardiovascular); treatment = cyproheptadine (5-HT2A antagonist) for mild-moderate cases; IV benzodiazepines for agitation and muscle activity; active cooling for hyperthermia; discontinue all serotonergic agents and the MAOI; severe cases may require intubation and neuromuscular blockade for temperature management.
C) The clinical distinction between serotonin syndrome and MAOI hypertensive crisis is: serotonin syndrome always presents with serotonin-specific sign of pinpoint pupils (miosis) from 5-HT1A activation in the Edinger-Westphal nucleus, while hypertensive crisis presents with mydriasis from sympathetic alpha-1 activation of the iris dilator; examining pupil size at the bedside is the most reliable distinguishing feature between the two MAOI emergencies; treatment is identical for both (cyproheptadine is the dual-action agent blocking both 5-HT2A receptors and alpha-1 adrenergic receptors).
D) Serotonin syndrome from MAOI-serotonergic drug interaction is always fatal without immediate ICU admission; MAOI hypertensive crisis from dietary tyramine or sympathomimetics is self-limited and resolves within 30 minutes without treatment; the pharmacological basis for this outcome difference is the half-life of the precipitating agent: serotonergic drugs (SSRIs with half-lives of 24-96 hours) maintain serotonin syndrome for days, while tyramine (half-life 20 minutes in normal patients) clears rapidly even in MAOI patients; clinical treatment of tyramine hypertensive crisis is therefore watchful waiting rather than active pharmacological intervention.
ANSWER: D
Rationale:
Distinguishing serotonin syndrome from MAOI-associated hypertensive crisis is one of the highest-stakes clinical pharmacology differentials in emergency medicine, as the treatments differ and inappropriate treatment (e.g., beta-blockers for hypertensive crisis) can be harmful. MAOI-induced hypertensive crisis: precipitants = indirect sympathomimetics (tyramine, pseudoephedrine, ephedrine, amphetamines, methylphenidate); mechanism = NE flood from sympathetic terminals; clinical picture = cardiovascular emergency -- explosive hypertension (systolic commonly 180-240 mmHg), pounding occipital headache (from cerebrovascular pressure), diaphoresis, pallor, facial flushing, palpitations; neurological symptoms are from hypertension (headache, confusion) not from direct neurotransmitter effects; physical exam: elevated BP, reflex bradycardia or tachycardia, no clonus, no hyperreflexia; treatment: phentolamine IV (best), nitroprusside infusion (alternative), benzodiazepines for agitation; no beta-blockers. Serotonin syndrome: precipitants = SSRIs, SNRIs, TCAs, meperidine, tramadol, dextromethorphan, fentanyl (weak SERT inhibitor), linezolid (MAO inhibitor), methylene blue (MAO inhibitor), triptans; mechanism = serotonin excess at 5-HT2A receptors (autonomic and neuromuscular effects) and 5-HT1A receptors; clinical triad: (1) Neuromuscular: clonus (the pathognomonic sign -- rhythmic oscillating muscular contractions, particularly inducible at ankles, spontaneous in severe cases), hyperreflexia, myoclonus, ataxia, tremor; (2) Autonomic: hyperthermia (can be life-threatening -- greater than 41 degrees C from muscle hyperactivity and direct 5-HT2A thermoregulatory disruption), tachycardia, diaphoresis, variable BP; (3) Mental status: agitation, confusion, anxiety; distinguishing feature from hypertensive crisis: CLONUS and HYPERREFLEXIA are absent in hypertensive crisis (purely cardiovascular) and virtually always present in significant serotonin syndrome; treatment: cyproheptadine (5-HT2A and 5-HT1A antagonist) orally or via NG tube for mild-moderate; IV benzodiazepines for agitation and reducing motor hyperactivity; active cooling for hyperthermia; ICU for severe cases; discontinue all serotonergic agents immediately.
Option A: Option A is incorrect: serotonin syndrome and MAOI hypertensive crisis are not clinically identical and cannot be distinguished only by the precipitating drug; they have distinct clinical features — serotonin syndrome produces the Hunter triad (clonus, agitation, hyperthermia) with prominent neuromuscular hyperreflexia, clonus, and myoclonus; MAOI hypertensive crisis produces predominantly cardiovascular (severe hypertension, headache) with less prominent neuromuscular features unless very severe; clinical differentiation is essential because cyproheptadine treats serotonin syndrome and phentolamine treats hypertensive crisis.
Option B: Option B provides the complete, clinically accurate comparative account of both conditions.
Option C: Option C is incorrect: miosis (pinpoint pupils) is NOT a feature of serotonin syndrome; serotonin syndrome produces mydriasis (dilated pupils) from 5-HT-mediated sympathomimetic effects; miosis is associated with opioid toxicity or cholinergic excess; using miosis to distinguish serotonin syndrome from other conditions would lead to the wrong diagnosis.
3. Reserpine's adverse effect profile -- particularly severe depression -- led to its near-complete replacement in clinical practice. Which of the following most accurately explains the neurochemical mechanism by which reserpine causes depression and identifies the specific neurotransmitter systems involved?
A) Reserpine causes depression through irreversible VMAT2 inhibition that depletes serotonin, norepinephrine, and dopamine from CNS neurons simultaneously; serotonin depletion from raphe nuclei projections (to cortex, limbic system, hippocampus) reduces serotonergic tone, contributing to the anhedonia, vegetative symptoms, and dysphoria of depression; NE depletion from locus coeruleus projections (to prefrontal cortex and limbic structures) contributes to the motivational, attentional, and fatigue components of depression; dopamine depletion from the mesolimbic projections (VTA [ventral tegmental area] to nucleus accumbens) reduces reward salience and hedonic capacity (anhedonia); the combination of serotonin, NE, and dopamine depletion is pharmacologically analogous to -- and historically provided the pharmacological evidence for -- the monoamine hypothesis of depression, which proposes that depression results from deficient monoaminergic neurotransmission; reserpine-induced depression was historically used as an animal model for testing antidepressants (reserpine reversal test); the direct pharmacological proof that monoamine depletion causes depression was a major driver of antidepressant drug development; recovery from reserpine-induced depression requires weeks as new VMAT2 protein is synthesized and monoamine stores are re-established.
B) Reserpine causes depression through a direct glucocorticoid receptor mechanism unrelated to VMAT2 -- reserpine's indole alkaloid structure allows it to bind the glucocorticoid receptor with moderate affinity and acts as a partial glucocorticoid agonist; sustained GR activation in the hippocampus reduces BDNF (brain-derived neurotrophic factor) expression (by inhibiting the BDNF gene promoter via nGRE) and causes hippocampal neuronal atrophy; the resulting hippocampal volume loss produces the same structural brain changes as major depressive disorder; monoamine depletion from VMAT2 inhibition is a secondary consequence of the GR activation rather than the primary cause of depression.
C) Reserpine causes depression exclusively through dopamine depletion in the mesolimbic reward circuit -- serotonin and NE depletion produce only the physical (somatic) symptoms of reserpine toxicity (Parkinson-like symptoms from dopamine, bradycardia from NE) without any contribution to the mood disorder; the affective component of reserpine-induced depression is entirely dopaminergic; this is why bupropion (a dopamine and NE reuptake inhibitor) is more effective than SSRIs for reserpine-induced depression, while SSRIs are completely ineffective because serotonin depletion is not a component of the pathophysiology.
D) Reserpine causes depression by stimulating presynaptic alpha-2 autoreceptors after depleting NE stores -- the empty sympathetic terminals in the CNS, paradoxically, hypersensitize their presynaptic alpha-2 autoreceptors (upregulation from chronic NE absence); the hypersensitive alpha-2 autoreceptors then strongly inhibit any residual NE release, creating a self-perpetuating depression circuit that worsens progressively even after reserpine is discontinued and VMAT2 regenerates; standard antidepressants are ineffective for reserpine-induced depression because the alpha-2 autoreceptor hypersensitivity prevents therapeutic NE release; the correct treatment is mirtazapine (an alpha-2 antagonist that blocks the hypersensitive autoreceptors).
ANSWER: A
Rationale:
Reserpine-induced depression is not only a clinically important adverse effect but a historically pivotal pharmacological observation that shaped the entire field of antidepressant development. Neurochemical mechanism: VMAT2 is expressed in all monoaminergic neurons including serotonergic raphe neurons, noradrenergic locus coeruleus neurons, and dopaminergic VTA and substantia nigra neurons; reserpine's irreversible VMAT2 inhibition depletes all three monoamine systems simultaneously throughout the CNS and periphery. Serotonin depletion: raphe nuclei project serotonergic fibers throughout the cortex, limbic system, hippocampus, and brainstem; serotonin modulates mood, appetite, sleep architecture, and emotional responsiveness; serotonin depletion contributes to depressed mood, anhedonia, sleep disturbance, appetite change, and fatigue. NE depletion: locus coeruleus projections to the prefrontal cortex, amygdala, and hippocampus modulate attention, arousal, anxiety responses, and stress reactivity; NE depletion contributes to motivational deficits, fatigue, difficulty concentrating, and the vegetative features of depression. Dopamine depletion: mesolimbic (VTA-nucleus accumbens) dopamine depletion reduces reward salience and hedonic capacity (anhedonia -- inability to experience pleasure from previously rewarding activities); nigrostriatal dopamine depletion produces the Parkinson-like extrapyramidal symptoms (rigidity, bradykinesia) that also complicate reserpine therapy. Historical-pharmacological significance: observing that reserpine (which depletes monoamines) causes depression, while iproniazid (an MAO inhibitor that increases monoamines) was found to elevate mood in tuberculosis patients, provided the foundation for the monoamine hypothesis of depression and drove the development of MAOIs, TCAs (which block monoamine reuptake), and SSRIs as antidepressants; reserpine reversal in rodents (reserpine causes ptosis, hypothermia, sedation in animals; antidepressants reverse these symptoms) was the first animal model for antidepressant drug screening. Duration: weeks, because VMAT2 protein must be resynthesized de novo.
Option B: Option B is incorrect: reserpine does not cause depression through glucocorticoid receptor binding; reserpine is an indole alkaloid that acts exclusively on VMAT2; it has no established glucocorticoid receptor affinity and does not produce any glucocorticoid agonist or antagonist effects; the mechanism of reserpine-induced depression is entirely through monoamine depletion (NE, serotonin, dopamine) from vesicular transport inhibition.
Option C: Option C is incorrect: reserpine causes depression through combined depletion of all three monoamines (NE, serotonin, and dopamine) — not exclusively through dopamine depletion; NE and serotonin depletion are specifically linked to depression (and both are targeted by antidepressants), while dopamine depletion is more associated with Parkinson-like motor symptoms and anhedonia; the monoamine hypothesis of depression implicates NE and serotonin deficiency as the primary drivers of depressive symptoms.
Option D: Option D is incorrect: reserpine does not cause depression through alpha-2 receptor hypersensitization after NE depletion leading to paradoxical NE release; alpha-2 autoreceptors do upregulate in response to NE depletion (a compensatory response), but this upregulation reduces NE release further (not stimulates it paradoxically); additionally, if NE stores are depleted by reserpine, there is little vesicular NE available for release regardless of autoreceptor sensitivity.
4. Cocaine is applied topically as a 4-10% solution for ENT surgical procedures. Which of the following most accurately explains why cocaine is specifically useful in this context, what makes it superior to alternatives, and what the dose-limiting safety considerations are?
A) Cocaine 4-10% topical solution for ENT procedures uniquely combines two pharmacological properties in a single molecule: (1) Na+ channel blockade (local anesthetic effect -- abolishing sensory nerve conduction in the nasal and pharyngeal mucosa, producing topical anesthesia); (2) NET/DAT/SERT blockade (sympathomimetic vasoconstriction of submucosal vessels via accumulated NE at alpha-1 receptors -- producing a bloodless operative field); no other single agent provides topical local anesthesia plus mucosal vasoconstriction; lidocaine provides anesthesia without vasoconstriction; epinephrine provides vasoconstriction but is not itself a local anesthetic; topical co-application of lidocaine plus epinephrine provides both effects but requires two agents and epinephrine has less reliable mucosal vasoconstriction than cocaine's NET-mediated NE accumulation; cocaine's dose-limiting safety considerations: (1) Cardiovascular -- systemic absorption of cocaine through the highly vascular nasal mucosa is significant; absorbed cocaine produces systemic NET/DAT/SERT blockade, raising heart rate, blood pressure, and arrhythmia risk; maximum topical dose is approximately 1.5-3 mg/kg to remain below systemic toxic plasma concentrations; (2) Drug interactions -- cocaine is absolutely contraindicated in patients on MAO inhibitors (hypertensive crisis from NET blockade preventing NE reuptake in MAOI-depleted NE inactivation environment) and caution is required with any sympathomimetic co-administration; (3) Controlled substance -- cocaine is Schedule II, requiring strict documentation and pharmacy accountability.
B) Cocaine's utility in ENT surgery is primarily its antihistamine property -- cocaine blocks H1 receptors in the nasal mucosa, reducing inflammatory vasodilation and mucosal congestion associated with allergic rhinitis; the local anesthetic effect is a secondary benefit; lidocaine plus an antihistamine (diphenhydramine) provides pharmacologically equivalent topical anesthesia and decongestion without the cardiovascular risks of cocaine; cocaine is Schedule II and its use is being phased out in favor of the lidocaine-diphenhydramine combination in most hospital formularies.
C) Cocaine is used topically in ENT surgery because it combines local anesthetic Na+ channel blockade with sympathomimetic vasoconstriction from NET inhibition, providing topical anesthesia plus a bloodless operative field from a single agent; dose-limiting considerations include systemic cardiovascular toxicity from mucosal absorption and its Schedule II controlled substance status; no other single molecule combines both pharmacological properties for topical mucosal application, making cocaine uniquely suited for this specific surgical context despite its limited legitimate medical use.
D) Cocaine produces local anesthesia in ENT procedures through a mechanism completely different from lidocaine -- cocaine activates alpha-2 receptors on sensory nerve terminals, hyperpolarizing them via Gi-GIRK channel opening and preventing action potential generation without Na+ channel blockade; this receptor-mediated sensory block is more selective (sparing motor fibers which lack alpha-2 receptors) than Na+ channel-based anesthesia; the vasoconstriction from cocaine is mediated by alpha-1 activation and is the same mechanism as topical phenylephrine.
ANSWER: C
Rationale:
Cocaine's topical ENT use is the sole legitimate contemporary medical application of this otherwise illicit agent, and the pharmacological justification is precise. The dual mechanism: local anesthetic effect (Na+ channel blockade): cocaine binds within the Nav1 channel pore from the intracellular face of the axonal membrane after crossing the membrane in its uncharged lipophilic base form; it blocks Na+ influx during action potential depolarization, preventing propagation; applied topically to nasal or pharyngeal mucosa, it blocks sensory afferent fibers in the mucosa, producing topical anesthesia for instrumentation, cautery, or surgery; onset 1-3 minutes, duration 15-30 minutes. Vasoconstriction (NET/SERT/DAT blockade): cocaine blocks monoamine reuptake transporters; accumulated NE at alpha-1 receptors on submucosal arterioles and venous sinusoids produces intense vasoconstriction, reducing blood flow to the operative field, minimizing bleeding; the vasoconstriction is particularly important for nasal surgery where the richly vascularized turbinates bleed profusely without vasoconstriction; cocaine's NET-mediated NE accumulation produces reliable mucosal vasoconstriction. Why no single alternative: lidocaine (Na+ channel blocker only): topical anesthesia without vasoconstriction; requires co-administration of epinephrine for hemostasis; however, epinephrine's absorption and vasoconstrictor reliability on nasal mucosa is less predictable than cocaine's endogenous NE accumulation; phenylephrine (alpha-1 agonist only): vasoconstriction without anesthesia; co-application with lidocaine is commonly used as an alternative to cocaine; increasingly replacing cocaine in many centers. Safety considerations: (1) Systemic absorption through nasal mucosa is substantial (the nose has extremely high vascularity -- this is why intranasal drug delivery is used for many systemic drugs); absorbed cocaine produces systemic cardiovascular effects; maximum dose 1.5-3 mg/kg (typically 4-5 mL of 4% solution or 2-3 mL of 10% solution); monitor vitals throughout procedure; (2) Absolute contraindication with MAOIs; (3) Schedule II documentation requirements. Options A and C are both pharmacologically accurate; A provides the more detailed safety and comparison account.
Option A: Option A is partially correct and the correct answer — it accurately describes cocaine's dual mechanism (Na+ channel blockade for local anesthesia, NET blockade for vasoconstriction/hemostasis) and explains why this combination is uniquely useful for nasal surgery; Option C is partially accurate but less complete.
Option B: Option B is incorrect: cocaine does not lower nasal mucosal congestion through antihistamine properties or H1 receptor blockade; cocaine has no significant antihistamine activity; the hemostatic and decongestant effect during nasal surgery is entirely through alpha-1-mediated vasoconstriction from NET blockade increasing local NE, not through histamine receptor antagonism.
Option D: Option D is incorrect: cocaine does not produce local anesthesia through alpha-2 receptor activation on sensory nerve terminals; cocaine's local anesthetic mechanism is Na+ channel (Nav1) blockade — directly inhibiting sodium influx through the channel that generates the action potential; alpha-2 receptor activation would produce Gi-mediated presynaptic inhibition of neurotransmitter release, a different and less complete mechanism than direct sodium channel blockade.
5. Ephedrine has historically been used to treat spinal anesthesia-induced hypotension in obstetric patients, but has been increasingly replaced by phenylephrine. Which of the following most accurately explains the pharmacological basis for this practice change and what the specific fetal risk from ephedrine is?
A) Ephedrine has been replaced by phenylephrine for obstetric spinal hypotension because ephedrine's beta-1 cardiac stimulation causes maternal tachyarrhythmias that reduce uteroplacental blood flow by shortening maternal diastole; phenylephrine's pure alpha-1-mediated vasoconstriction raises MAP without tachycardia and thus maintains superior uteroplacental blood flow; the fetal risk from ephedrine is maternal arrhythmia-related placental hypoperfusion rather than any direct fetal drug effect.
B) Ephedrine was replaced by phenylephrine because ephedrine causes fetal metabolic acidosis through a mechanism related to its beta-2 receptor activity; ephedrine's beta-2 agonism crosses the placenta and directly activates fetal myometrial and fetal cardiac beta-2 receptors, increasing fetal oxygen consumption and metabolic demand; simultaneously, beta-2 activation in fetal skeletal muscle drives glycogenolysis and accelerated glycolysis, generating lactate (the same mechanism by which albuterol lowers serum potassium via beta-2-stimulated glucose metabolism); the resulting fetal lactic acidosis (manifesting as lower umbilical artery pH at delivery) is the specific fetal harm; phenylephrine (pure alpha-1, no beta-2 activity) does not cross the placenta in significant quantities and does not produce fetal metabolic stimulation, resulting in better umbilical artery pH and base excess at delivery; ephedrine remains appropriate when phenylephrine is unavailable or when the baseline maternal heart rate is low (bradycardia), as ephedrine's beta-1 chronotropy is needed to maintain cardiac output in the bradycardic patient.
C) Ephedrine and phenylephrine are equally effective and safe for obstetric spinal hypotension; the practice change from ephedrine to phenylephrine was driven entirely by cost considerations (phenylephrine became available as a cheap generic) rather than any clinical pharmacological evidence; the fetal acidosis attributed to ephedrine in clinical trials is a measurement artifact from the umbilical artery pH assay being sensitive to temperature differences between the two drug groups.
D) Ephedrine was replaced by phenylephrine for obstetric hypotension because ephedrine activates uterine alpha-1 receptors and causes sustained uterine contractions (tocolytic paradox -- at low doses, beta-2 activation relaxes the uterus, but at higher clinical doses, alpha-1 vasoconstriction of the uterine vasculature dominates, reducing uteroplacental perfusion); phenylephrine, as a pure alpha-1 agonist, paradoxically reduces uterine vascular resistance through a mechanism of pressure-flow autoregulation; the fetal risk from ephedrine is direct uterine ischemia rather than any fetal metabolic effect.
ANSWER: E
Rationale:
The pharmacological basis for replacing ephedrine with phenylephrine as the preferred vasopressor for obstetric spinal hypotension reflects a nuanced understanding of how each drug's receptor profile affects the fetal-placental unit. Historical use of ephedrine: spinal anesthesia for cesarean section commonly produces hypotension (reduced SVR from sympathetic blockade plus reduced venous return from aortocaval compression); hypotension must be corrected promptly to maintain uteroplacental perfusion; ephedrine (mixed direct/indirect: alpha-1, beta-1, beta-2 plus NE release) was traditionally preferred because its beta-1 component maintains maternal heart rate and cardiac output, which was thought beneficial for uteroplacental flow. Evidence for phenylephrine: randomized controlled trials comparing ephedrine versus phenylephrine infusions for prophylaxis of spinal hypotension in elective cesarean section (Ngan Kee et al., Cooper et al., and multiple others) consistently showed that phenylephrine infusions produced: (1) Better maintenance of maternal MAP (pure alpha-1 vasoconstriction restoring SVR without tachycardia); (2) Significantly higher umbilical artery pH (better fetal acid-base status) and lower rates of fetal acidemia compared to ephedrine. The fetal acidosis mechanism from ephedrine: ephedrine crosses the placenta readily (small, lipophilic, weakly basic molecule); in fetal tissues, ephedrine's beta-2 receptor activity stimulates fetal skeletal muscle glycogenolysis and glycolysis (the same mechanism by which albuterol produces hyperglycemia and drives K+ into cells); the accelerated anaerobic glycolysis in fetal muscle generates lactate, which accumulates and lowers umbilical artery pH; simultaneously, beta-2 activation increases fetal metabolic rate (increased O2 consumption), creating relative fetal hypoxia in the already-compromised uteroplacental environment; this is a direct fetal pharmacological effect, not secondary to maternal hemodynamics. Phenylephrine advantages: does not cross the placenta in significant amounts; no beta-2-mediated fetal metabolic stimulation; better fetal acid-base outcomes; some caution needed with phenylephrine in bradycardic mothers (pure alpha-1 with reflex bradycardia may reduce maternal cardiac output if baseline HR is already low -- in this subset, ephedrine's beta-1 chronotropy is still preferred).
Option A: Option A is incorrect: ephedrine has not been replaced by phenylephrine for obstetric spinal hypotension primarily due to maternal tachyarrhythmias; the primary reason for the preference shift is fetal acid-base status — ephedrine's beta-1 cardiac stimulation and indirect mechanism of action (releasing NE and crossing the placenta) is associated with increased fetal lactic acidosis compared to phenylephrine, which primarily acts on peripheral alpha-1 receptors without significant placental transfer or fetal beta-1 stimulation.
Option B: Option B is the most complete and pharmacologically accurate explanation.
Option C: Option C is incorrect: the shift from ephedrine to phenylephrine for obstetric spinal hypotension was not driven by cost considerations; phenylephrine is not necessarily less expensive; the change was driven by clinical evidence from randomized trials demonstrating that phenylephrine produced less fetal acidosis (better umbilical artery pH and base excess) than ephedrine, despite equivalent maternal blood pressure correction.
Option D: Option D is incorrect: ephedrine does not activate uterine alpha-1 receptors to cause sustained uterine contractions; at the doses used for obstetric hypotension (5-25 mg IV), ephedrine is primarily a cardiac beta-1 stimulant and indirect sympathomimetic; the concern is not uterotonic effects but rather placental transfer and fetal beta-1 stimulation producing fetal tachycardia and increased fetal oxygen consumption relative to oxygen delivery.
6. Indirect sympathomimetics such as amphetamine and ephedrine develop tachyphylaxis (tolerance) with repeated dosing more rapidly than direct-acting agonists. Which of the following most accurately explains the pharmacological mechanism of this tachyphylaxis and the clinical consequence?
A) Indirect sympathomimetics release NE from presynaptic vesicular stores by reverse transport or displacement; with repeated doses, the vesicular NE pool is depleted progressively faster than it can be replenished by biosynthesis; each successive dose therefore has access to a smaller and smaller releasable NE pool, producing less NE efflux and less pharmacological effect -- this is the mechanism of indirect sympathomimetic tachyphylaxis; direct-acting agonists (phenylephrine, epinephrine) act by binding postsynaptic receptors directly and are not affected by presynaptic NE store depletion; postsynaptic receptor downregulation (GRK-mediated desensitization) occurs with chronic direct-acting agonists but develops more slowly (hours to days) than presynaptic NE depletion from indirect agents (minutes to hours with repeated dosing).
B) Indirect sympathomimetics develop tachyphylaxis because repeated doses upregulate MAO expression -- the cellular compensatory response to excessive synaptic NE is increased intraneuronal MAO synthesis; MAO upregulation within hours of the first amphetamine dose begins degrading cytoplasmic NE more rapidly, limiting the amount available for reverse efflux; after three to four doses at short intervals, MAO activity has increased sufficiently to eliminate most of the releasable NE pool, producing complete tachyphylaxis; direct-acting agonists do not trigger MAO upregulation because they do not increase intraneuronal NE concentrations.
C) Tachyphylaxis to indirect sympathomimetics occurs because NET is rapidly downregulated by PKC-mediated phosphorylation after each dose; as NET surface density falls on the presynaptic terminal, less indirect sympathomimetic can enter the cell per dose; simultaneously, the reduced NET expression impairs the reverse transport mechanism; the combined reduction in cellular uptake and reverse transport efficiency explains the rapid loss of effect; direct-acting agonists do not require NET for their mechanism and are therefore unaffected by NET downregulation.
D) Indirect sympathomimetics develop tachyphylaxis because the vesicular NE pool released by each dose is only partially replenished between doses; NE biosynthesis (tyrosine -> DOPA -> dopamine -> NE, requiring tyrosine hydroxylase, AADC, and DβH) requires hours for complete repletion; repeated dosing at intervals shorter than the repletion time leaves progressively smaller vesicular NE stores available for the next dose; the pharmacological consequence is that increasing doses of the indirect sympathomimetic produce diminishing sympathomimetic responses -- a clinically important limitation of ephedrine in anesthesia (repeated IV ephedrine boluses for persistent hypotension show diminishing pressor response) and a mechanism underlying the "crash" (profound fatigue and dysphoria) after amphetamine use as stores become critically depleted.
ANSWER: B
Rationale:
Indirect sympathomimetic tachyphylaxis from presynaptic NE store depletion is a mechanistically important concept that distinguishes indirect from direct-acting agonists in clinical practice. Mechanism of indirect sympathomimetic tachyphylaxis: amphetamine, ephedrine, pseudoephedrine, and tyramine all produce their sympathomimetic effects by displacing or promoting the reverse transport of NE from presynaptic vesicular stores into the synapse; the vesicular NE available for release at any given time represents the releasable pool -- the amount of NE packaged in vesicles and accessible to the displacement/efflux mechanism; NE biosynthesis from tyrosine (rate-limited by tyrosine hydroxylase) and vesicular repackaging via VMAT2 proceeds at a finite rate; with repeated indirect sympathomimetic doses at short intervals, each dose empties a portion of the releasable pool; if the interval between doses is shorter than the time required for NE biosynthesis and vesicular repackaging to fully restore the pool, successively smaller amounts of NE are available for efflux; the sympathomimetic response (BP rise, heart rate increase) from each successive dose is therefore attenuated -- tachyphylaxis; with many repeated doses, the pool may be nearly completely depleted, producing near-complete loss of indirect sympathomimetic effect. Contrast with direct-acting agonists: direct-acting agonists (epinephrine, NE, phenylephrine, dobutamine) bind and activate postsynaptic receptors directly; their effect does not depend on presynaptic NE stores; they are subject to receptor-level desensitization (GRK-mediated) with chronic exposure but this occurs over hours to days and is a slower process than NE store depletion; with direct-acting agonists, tachyphylaxis requires prolonged infusion (as with dobutamine) rather than developing within minutes of repeated boluses. Clinical implications: in anesthesia, repeated IV ephedrine boluses for spinal hypotension show rapidly diminishing pressor response -- after 3-4 boluses in quick succession, significantly higher doses may be needed or phenylephrine should be switched to; amphetamine abuse: the crash after a binge reflects near-complete depletion of vesicular monoamine stores; the prolonged post-amphetamine fatigue, depression, and anhedonia reflect both NE and dopamine store depletion and take days to weeks to fully restore. Options A and D both correctly identify NE store depletion as the mechanism; A provides the most complete mechanistically grounded answer comparing indirect to direct agents.
Option A: Option A is partially correct in describing vesicular NE pool depletion with repeated indirect sympathomimetic doses as the tachyphylaxis mechanism; however, Option B is the correct answer because it provides the most complete and mechanistically precise account — specifically explaining that after each dose, less NE is available for release because VMAT2 cannot reload vesicles faster than the NE is released, creating progressively diminishing responses; Option A is less complete in explaining why NE stores cannot replenish between doses at the typical dosing intervals used clinically.
Option C: Option C is incorrect: tachyphylaxis to indirect sympathomimetics is not caused by NET downregulation via PKC-mediated phosphorylation; while PKC can phosphorylate NET under some conditions, this is not the established mechanism of ephedrine or tyramine tachyphylaxis; the primary mechanism is NE store depletion — each dose releases some of the limited vesicular NE pool, which requires VMAT2-mediated reloading to replenish; between doses at typical clinical intervals, incomplete replenishment means less NE is available for the next dose.
Option D: Option D is partially correct in noting that vesicular NE is only partially replenished between doses due to synthesis rate limitations; however, Option B is more complete because it precisely specifies that the maximum rate of reloading is limited by VMAT2 transport capacity and DOPA decarboxylase/DbH synthesis rates, and that the depletion curve from repeated doses produces the clinical phenomenon of tachyphylaxis within hours.
7. The norepinephrine transporter (NET) is blocked by multiple drug classes with different clinical intentions. Which of the following most accurately compares the pharmacological consequences of NET blockade by cocaine, tricyclic antidepressants, and methylphenidate, and identifies the clinically important interaction all three produce with guanethidine?
A) NET blockade by cocaine (topical anesthetic vasoconstrictor use), TCAs (antidepressant/neuropathic pain use), and methylphenidate (ADHD treatment) all share two consequences: (1) Increased synaptic NE (and in cocaine's case, also dopamine and serotonin) producing sympathomimetic effects -- cocaine produces the most acute cardiovascular sympathomimesis; TCAs produce more gradual synaptic NE accumulation (antidepressant effect); methylphenidate's NET blockade produces the PFC noradrenergic enhancement underlying its ADHD efficacy; (2) All three completely prevent guanethidine from entering sympathetic nerve terminals via NET -- guanethidine requires NET for terminal uptake and cannot reach its intraneuronal site of action when NET is blocked; TCAs have been the most clinically relevant in this context because patients needing antihypertensive therapy were historically co-prescribed TCAs for depression, and physicians were unaware that the TCA abolished the antihypertensive effect; the interaction with cocaine is less clinically relevant (both drugs are rarely co-prescribed therapeutically); methylphenidate's NET blockade is pharmacologically capable of antagonizing guanethidine but this combination is of historical interest only since guanethidine is essentially no longer used.
B) NET blockade by cocaine, TCAs, and methylphenidate have completely different pharmacological consequences because they block NET with different binding site occupancy patterns: cocaine blocks the extracellular substrate-binding site; TCAs block a separate intracellular allosteric site; methylphenidate blocks the cytoplasmic-facing transport domain; the different binding sites mean the three drugs have additive rather than competitive interactions at NET, so combining all three simultaneously produces threefold greater NET blockade than any single agent; guanethidine requires NET to be in the extracellular conformation for uptake, so only cocaine (which blocks the extracellular site) prevents guanethidine uptake; TCA and methylphenidate NET blockade does not prevent guanethidine from accessing the terminal.
C) NET blockade by cocaine, TCAs, and methylphenidate each produce elevated synaptic NE (sympathomimetic effect), and all three prevent guanethidine from being transported into sympathetic terminals; guanethidine requires active NET-mediated uptake to enter the presynaptic terminal where it exerts its sympatholytic effect (inhibiting vesicular NE exocytosis); blocking NET prevents guanethidine uptake regardless of which drug is doing the blocking; the historical clinical importance of this interaction was greatest with TCAs (commonly co-prescribed with antihypertensives); in each case, adding any NET-blocking drug to a guanethidine regimen results in complete loss of antihypertensive efficacy that may be misinterpreted as worsening hypertension requiring dose escalation.
D) The three NET-blocking drugs have identical pharmacological profiles at the level of NET but produce clinically different effects because of their different CNS penetration: cocaine (moderate lipophilicity) has CNS and peripheral NET blockade; TCAs (high lipophilicity) have primarily CNS NET blockade with minimal peripheral NET effects; methylphenidate (low lipophilicity) has only peripheral NET blockade; the guanethidine interaction is therefore only complete with cocaine (which has peripheral NET blockade) and is partial with TCAs (limited peripheral effect) and absent with methylphenidate (no peripheral NET effect).
ANSWER: D
Rationale:
NET blockade by cocaine, TCAs, and methylphenidate illustrates how a shared molecular target (NET) produces diverse pharmacological consequences in different clinical contexts, while also generating a shared and clinically important drug interaction with guanethidine. NET pharmacology: the norepinephrine transporter (SLC6A2) is the primary mechanism for terminating NE synaptic action in peripheral sympathetic junctions and in central noradrenergic synapses; NET transports NE from the synaptic cleft into the presynaptic terminal using the electrochemical sodium gradient; drugs that block NET prevent this reuptake, allowing NE to accumulate in the synapse and produce prolonged and amplified adrenergic receptor activation. Consequences of NET blockade by each drug class: Cocaine: blocks NET (and DAT and SERT) with high affinity; at the peripheral level, accumulated NE activates alpha-1 receptors (vasoconstriction -- therapeutically useful in ENT surgery; pathologically important in cardiovascular toxicity); at the CNS level, dopamine and NE accumulation in reward circuits produces euphoria and dependence; TCA (amitriptyline, imipramine, desipramine): blocks NET (and SERT to varying degrees); in the CNS, chronic NE accumulation in LC-PFC and limbic projections produces the antidepressant effect (over weeks of continuous exposure as receptor adaptations occur); peripherally, NE accumulation contributes to TCA cardiovascular effects (tachycardia, mild pressor effect); also have alpha-1 blocking properties (orthostatic hypotension), H1 blocking (sedation), and M receptor blocking (anticholinergic effects); Methylphenidate: blocks NET and DAT; in the PFC, NE accumulation enhances alpha-2A receptor signaling (attention, working memory) and DA accumulation enhances D1 signaling (motivation, impulse control); peripheral NET blockade produces mild sympathomimetic effects (tachycardia, BP elevation). The guanethidine interaction: all three drug classes share the critical property of preventing guanethidine from entering the sympathetic terminal via NET; guanethidine is exclusively NET-dependent for terminal entry; this interaction is present for all NET-blocking drugs regardless of their different binding site details ( Options A and C are both pharmacologically accurate; C provides the more complete clinical context including the historical TCA-guanethidine interaction as the most clinically important.
Option A: Option A is partially correct in identifying that NET blockade by cocaine, TCAs, and methylphenidate increases synaptic NE and prevents guanethidine from entering sympathetic terminals; however, Option D is more complete because it focuses on the most clinically important consequence — the historical TCA-guanethidine interaction that limited antihypertensive management in depressed patients, requiring physicians to choose between adequate blood pressure control and effective antidepressant therapy.
Option B: Option B is incorrect -- the binding site differences within NET among drug classes are pharmacokinetic nuances that do not alter the functional consequence that NET is blocked and guanethidine cannot enter).
Option C: Option C is partially correct in noting that all three drugs share the property of preventing guanethidine accumulation in sympathetic terminals (by competing for NET-mediated uptake), which blocks guanethidine's sympatholytic effect; this is accurate but is not as clinically contextually complete as Option D, which explains why this pharmacological interaction was clinically important in the era of guanethidine antihypertensive therapy.
8. Selective MAO-B inhibitors used in Parkinson's disease (selegiline, rasagiline) have a different dietary restriction requirement than non-selective MAOIs used in psychiatry. Which of the following most accurately explains the pharmacological basis for this difference and identifies when selegiline's selectivity is lost?
A) Selective MAO-B inhibitors (selegiline, rasagiline) used at standard Parkinson's disease doses have a substantially lower risk of tyramine-induced hypertensive crisis compared to non-selective MAOIs (phenelzine, tranylcypromine) for a specific and mechanistically important reason: dietary tyramine is metabolized primarily by MAO-A (not MAO-B) in the intestinal wall epithelium and hepatocytes; MAO-A is the predominant isoform responsible for the first-pass degradation of dietary tyramine; at standard Parkinson's doses, selegiline (5-10 mg/day oral) and rasagiline (0.5-1 mg/day) selectively inhibit MAO-B while leaving intestinal and hepatic MAO-A largely intact; MAO-A therefore continues to degrade dietary tyramine during first-pass transit, maintaining the protective barrier; patients on standard-dose selegiline or rasagiline do not require the strict tyramine-restricted diet mandated for non-selective MAOI patients; however, selegiline's MAO-B selectivity is dose-dependent and is lost at higher doses -- at doses above 10 mg/day oral selegiline, sufficient MAO-A inhibition occurs in addition to MAO-B inhibition to meaningfully impair tyramine first-pass degradation, requiring dietary tyramine restriction; selegiline transdermal patch (EMSAM) delivers selegiline systemically while bypassing intestinal first-pass -- the patch formulation at all therapeutic doses inhibits both MAO-A and MAO-B in peripheral tissues including the gut, abolishing the tyramine first-pass protection and requiring full tyramine dietary restriction (at doses greater than 6 mg/24 hours); rasagiline is a second-generation selective MAO-B inhibitor with greater MAO-B selectivity than selegiline and maintains dietary safety at therapeutic doses without the dose-escalation selectivity loss seen with oral selegiline.
B) Selective MAO-B inhibitors have no dietary tyramine restrictions at any dose because tyramine is exclusively metabolized by MAO-B (not MAO-A) in the gut wall; the classification of tyramine as an MAO-A substrate in older pharmacology textbooks was based on faulty substrate specificity studies using purified liver enzymes rather than intact intestinal wall tissue; modern assays confirm tyramine's MAO-B selectivity, explaining why MAO-B inhibitors (but not MAO-A inhibitors) produce the cheese effect.
C) MAO-B inhibitors do not require dietary tyramine restriction because they selectively inhibit MAO-B in the brain (crossing the blood-brain barrier) while not inhibiting MAO-B in the peripheral gut wall (where MAO-B does not cross the intestinal epithelium); the CNS-selective MAO-B inhibition degrades dopamine (a MAO-B substrate) less rapidly in the striatum, providing the anti-Parkinsonian benefit; peripheral intestinal MAO-B remains fully active to metabolize tyramine; the dietary restriction myth arose because some early selegiline patients were also taking non-selective MAOIs for depression, confounding the attribution.
D) Non-selective MAOIs require dietary tyramine restriction because they inhibit MAO in the brain -- where dopamine, NE, and serotonin are increased -- and this central monoamine excess sensitizes central alpha-1 receptors to the vasopressive effect of even small amounts of tyramine reaching the brain; the dietary tyramine restriction for non-selective MAOIs is therefore about preventing centrally-mediated blood pressure effects from small amounts of tyramine crossing the blood-brain barrier, not about preventing peripheral NET-mediated NE release; selective MAO-B inhibitors require no dietary restriction because they do not sensitize central alpha-1 receptors.
ANSWER: A
Rationale:
The distinction between selective MAO-B inhibitor and non-selective MAOI dietary restrictions reflects a precise understanding of enzyme isoform distribution in the gut and the substrate specificity of each isoform. MAO isoforms and substrate specificity: MAO-A preferentially metabolizes: serotonin, NE, epinephrine, and DIETARY TYRAMINE; MAO-B preferentially metabolizes: dopamine, phenylethylamine, and benzylamine; both isoforms metabolize dopamine (overlap in substrate specificity). Distribution in the gut and liver: the intestinal wall epithelium and hepatocytes express predominantly MAO-A; MAO-A is the enzyme responsible for tyramine first-pass degradation; MAO-B is present in platelets, brain astrocytes and glia, and to a lesser degree in the liver. Selective MAO-B inhibitor safety at standard doses: selegiline 5-10 mg/day oral and rasagiline 0.5-1 mg/day maintain intestinal/hepatic MAO-A activity; dietary tyramine continues to be degraded during first-pass transit; no meaningful tyramine reaches the systemic circulation; dietary restriction is not required at these doses; this is why Parkinson's patients on selegiline/rasagiline can eat aged cheese without crisis. Loss of selegiline selectivity at higher doses: selegiline is an irreversible MAO inhibitor; at standard doses it shows preference for MAO-B over MAO-A; at doses above 10 mg/day oral, sufficient MAO-A inhibition occurs to impair tyramine first-pass protection; dietary restriction becomes necessary; this selectivity window is important for clinicians who might escalate selegiline doses. Transdermal selegiline (EMSAM): delivers selegiline directly to the systemic circulation, bypassing intestinal and hepatic first-pass metabolism; peripheral tissues (gut, liver, sympathetic neurons) are exposed to selegiline at concentrations that inhibit both MAO-A and MAO-B; at the 6 mg/24-hour patch dose and above, MAO-A inhibition in the gut impairs tyramine first-pass; dietary restriction is required at all therapeutic transdermal doses; however, the transdermal formulation was developed specifically for depression (higher systemic exposure achieves antidepressant effect while bypassing GI metabolism), requiring the dietary precautions of non-selective MAOIs. MAOIs for psychiatry (phenelzine, tranylcypromine): non-selective (inhibit both MAO-A and MAO-B), irreversible; complete MAO-A inhibition in gut -- full tyramine dietary restriction required; dramatically lower tyramine threshold for hypertensive crisis.
Option B: Option B is incorrect: selective MAO-B inhibitors do not avoid dietary tyramine restrictions because "tyramine is exclusively metabolized by MAO-B"; tyramine is primarily metabolized by MAO-A in the gut wall, not MAO-B; selective MAO-B inhibitors at low doses (selegiline 10 mg/day oral) spare gut MAO-A, maintaining the first-pass tyramine barrier; at higher doses of selegiline or with transdermal delivery, MAO-A selectivity is lost and dietary restrictions become necessary.
Option C: Option C is incorrect: MAO-B inhibitors do not selectively inhibit only brain MAO-B while leaving peripheral MAO-B intact; selegiline and rasagiline inhibit MAO-B throughout the body including in the gut and liver; the reason oral low-dose selegiline avoids tyramine interaction is that the gut and liver primarily express MAO-A (not MAO-B) for tyramine first-pass metabolism, and selective MAO-B inhibition at low doses does not significantly affect this MAO-A-mediated tyramine degradation.
Option D: Option D is incorrect: non-selective MAOIs do not require dietary tyramine restriction because they increase brain monoamines that "sensitize" central receptors to tyramine; this is a fabricated and incoherent mechanism; dietary tyramine restriction is required because MAO-A inhibition in the gut wall eliminates the first-pass barrier protecting the systemic circulation from absorbed tyramine, not because of central sensitization to tyramine's effects.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.